Labcorp Files 8-K for Regulatory and Financial Reporting
Ticker: LH · Form: 8-K · Filed: Mar 27, 2024 · CIK: 920148
| Field | Detail |
|---|---|
| Company | Laboratory Corp Of America Holdings (LH) |
| Form Type | 8-K |
| Filed Date | Mar 27, 2024 |
| Risk Level | low |
| Pages | 1 |
| Reading Time | 2 min |
| Key Dollar Amounts | $0.10 |
| Sentiment | neutral |
Sentiment: neutral
Topics: regulatory-filing, sec-filing, financial-reporting
Related Tickers: LH
TL;DR
Labcorp filed a routine 8-K on 3/27/24 for disclosures. No major news.
AI Summary
Laboratory Corporation of America Holdings (Labcorp) filed an 8-K on March 27, 2024, to report information under Regulation FD and to file financial statements and exhibits. The filing does not contain specific financial figures or material events beyond the standard reporting requirements for this form.
Why It Matters
This filing indicates that Labcorp is adhering to its regulatory and financial disclosure obligations with the SEC. It serves as a routine update for investors and the public regarding the company's compliance.
Risk Assessment
Risk Level: low — This is a routine regulatory filing with no new material information or significant financial events disclosed.
Key Players & Entities
- Laboratory Corporation of America Holdings (company) — Registrant
- Labcorp (company) — Commonly known name for Registrant
- 358 South Main Street, Burlington, North Carolina 27215 (location) — Principal executive offices address
- March 27, 2024 (date) — Date of earliest event reported
FAQ
What is the primary purpose of this 8-K filing by Laboratory Corporation of America Holdings?
The primary purpose of this 8-K filing is to report information under Regulation FD and to file financial statements and exhibits, as indicated by the 'ITEM INFORMATION' section.
On what date was this 8-K filing made?
The 8-K filing was made on March 27, 2024.
What is the principal executive office address for Laboratory Corporation of America Holdings?
The address of the principal executive offices is 358 South Main Street, Burlington, North Carolina 27215.
Under which sections of the Securities Exchange Act of 1934 is this 8-K filed?
This 8-K is filed pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934.
Does this filing disclose any specific new financial results or material events?
Based on the provided text, this filing appears to be a routine disclosure for Regulation FD and financial statements/exhibits, and does not explicitly detail specific new financial results or material events.
Filing Stats: 438 words · 2 min read · ~1 pages · Grade level 11.5 · Accepted 2024-03-27 07:05:46
Key Financial Figures
- $0.10 — nge on which registered Common Stock , $0.10 par value LH New York Stock Exchange
Filing Documents
- lh-20240327.htm (8-K) — 24KB
- formpr1q24ex991earningsann.htm (EX-99.1) — 5KB
- lc2020logov2a.gif (GRAPHIC) — 5KB
- 0000920148-24-000016.txt ( ) — 160KB
- lh-20240327.xsd (EX-101.SCH) — 2KB
- lh-20240327_lab.xml (EX-101.LAB) — 22KB
- lh-20240327_pre.xml (EX-101.PRE) — 12KB
- lh-20240327_htm.xml (XML) — 3KB
01 Regulation FD Disclosure
Item 7.01 Regulation FD Disclosure Labcorp (NYSE: LH), a global leader of innovative and comprehensive laboratory services, will release its financial results for the first quarter of 2024 before the market opens on Thursday, April 25, 2024. The company will host a conference call and webcast beginning at 9 a.m. ET that day to discuss the results. The earnings press release and accompanying financial information will be posted on the Labcorp Investor Relations website.
01 Financial Statements and Exhibits
Item 9.01 Financial Statements and Exhibits. Exhibit Exhibit Name Exhibit 99.1 Press release dated March 27, 2024 issued by Labcorp
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. LABORATORY CORPORATION OF AMERICA HOLDINGS Registrant By: /s/ SANDRA VAN DER VAART Sandra van der Vaart Executive Vice President, Chief Legal Officer and Corporate Secretary March 27, 2024